Literature DB >> 597817

Some observations on the human pharmacology of methotrexate.

A H Calvert, P K Bondy, K R Harrap.   

Abstract

Plasma and urinary levels of methotrexate (MTX) have been measured enzymatically in 18 patients receiving doses of 5-1250 mg. When tritium-labeled MTX was administered, plasma levels measured by radioisotope counting were significantly higher than those measured enzymatically, the difference being accounted for by the presence of tritium label in plasma water as a result of drug metabolism. Renal clearance of MTX correlated well with glomerular filtration rate (GFR) and was consistently lower than the GFR, suggesting tubular reabsorption of the drug at the rate of urine flow studied. Plasma clearance measured by an infusion method was consistently greater than renal clearance, suggesting drug metabolism. Biliary MTX levels have been measured in three patients and are very much higher than plasma levels, suggesting a quantitatively important biliary recirculation of the drug. Plasma levels of MTX measured after 24 hours were not significantly different following iv or im administration, but were higher if an infusion was used.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 597817

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  16 in total

1.  Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker.

Authors:  J Hendel; H Brodthagen
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Rapid plasma clearance and reduced rate and extent of urinary elimination of parenterally administered methotrexate as a result of severe vomiting and diarrhoea.

Authors:  H W Van Den Berg; R F Murphy; D G Kennedy
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Authors:  V J Wiebe; C C Benz; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

4.  Effect of oral cholestyramine on the elimination of high-dose methotrexate.

Authors:  R Erttmann; G Landbeck
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

5.  Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.

Authors:  T Pignon; B Lacarelle; F Duffaud; P Guillet; J Catalin; A Durand; S Monjanel; R Favre
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Pharmacologic studies on the dibutyl and gamma-monobutyl esters of methotrexate in the rhesus monkey.

Authors:  A Rosowsky; H T Abelson; G P Beardsley; W D Ensminger; D W Kufe; G Steele; E J Modest
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

7.  Serum profiles and safety of intermediate-dose (500-1,000 mg) methotrexate following IV and IM administration.

Authors:  B M Colls; R A Robson; B A Robinson; G W Tisch
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells.

Authors:  S Cabral; S Leis; L Bover; M Nembrot; J Mordoh
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

9.  Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX.

Authors:  L Fahrig; H Brasch; H Iven
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.

Authors:  C R Pinkerton; S G Welshman; J G Kelly; R G Shanks; J M Bridges
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.